Single-site, country, and global licenses are multi-user, searchable, and cut-and-paste ready PDFs delivered by e-mail.
For Corporate Subscriptions, Multi-Reports Orders, Discounts
or Order Questions.
New to Insight Pharma Reports
is Prenatal Diagnostics: Invasive testing, noninvasive testing, and rising
maternal screening methods for preeclampsia and preterm labor. This report
discusses improvements in invasive procedures (karyotyping vs. cytogenetics),
and the rise of noninvasive screening methods and their impact on prenatal
healthcare. Although covering standard invasive procedure, this report focuses
on the noninvasive technologies either on the market or in development.
- Exclusive interviews with CEOs, CSOs, and Vice
Presidents from Sequenom, Verinata Health, Ariosa Diagnostics, Natera, Silicon
Biosystems, Metabolomic Diagnostics and NX PharmaGen
- Specifications of particular instruments
- Company goals, customer feedback, challenges
encountered, competitive advantage, platform pricing, and future endeavors.
- A survey capturing the demographics of the
prenatal industry is presented at the end of the report, specifically
highlighting organizational background, areas of research, challenges
encountered, and applications in development.
- Directory of companies within